Business Roundtable
Finance: Success Without an IPO - Creative Strategies for Achieving Liquidity
Tuesday, February 14, 2006
9:00 AM
Conrad Suite
With a plethora of private biotech companies and a fickle IPO window, VC's and bankers are increasingly looking at alternatives to the traditional IPO exit strategy. What can you do when the window is closed? SPACs, shells, reverse mergers?what are the differences? Are there advantages to using these and other options? Join us for a review of financing vehicles available to mezzanine-stage private companies, the pros and cons of each and a discussion on The Street's perception of alternative strategies for achieving liquidity.
Moderators
- Stephen M. Davis; Chair of the New York Business Practice and Co-Chair of the Venture Law Group, Heller Ehrman
Panelists
- Jack V. Talley; Chief Executive Officer, EpiCept Corp
- Jeffrey A. Rona; Vice President, Corporate Development, Corgentech Inc.
- Matthew N. Murray, Ph.D., CFA; Senior Biotechnology Analyst, Rodman & Renshaw, LLC
- Zachary C. Berk, O.D.; Managing Director, KBL Healthcare Acquisition Corp. II
- Julio J. Lugo; Vice President, ADR Group, The Bank of New York